United Therapeutics Profit Margin vs. Shares Owned By Institutions
| UTHR Stock | USD 400.45 0.42 0.10% |
United Therapeutics Net Profit Margin |
|
For United Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of United Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well United Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between United Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of United Therapeutics over time as well as its relative position and ranking within its peers.
United |
United Therapeutics' Revenue Breakdown by Earning Segment
Check out World Market Map.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.188 | Earnings Share 22.75 | Revenue Per Share 60.245 | Quarterly Revenue Growth 0.229 | Return On Assets 0.1189 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
United Therapeutics Shares Owned By Institutions vs. Profit Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining United Therapeutics's current stock value. Our valuation model uses many indicators to compare United Therapeutics value to that of its competitors to determine the firm's financial worth. United Therapeutics is rated first in profit margin category among its peers. It is rated below average in shares owned by institutions category among its peers producing about 243.49 of Shares Owned By Institutions per Profit Margin. At this time, United Therapeutics' Net Profit Margin is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value United Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.United Shares Owned By Institutions vs. Profit Margin
Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
United Therapeutics |
| = | 0.40 % |
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
United Therapeutics |
| = | 98.15 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
United Shares Owned By Institutions Comparison
United Therapeutics is currently under evaluation in shares owned by institutions category among its peers.
United Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in United Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, United Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of United Therapeutics' change in net profit over the period of time. It can combine multiple indicators of United Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -12.8 M | -13.4 M | |
| Operating Income | 1.2 B | 1.2 B | |
| Income Before Tax | 1.3 B | 1.3 B | |
| Total Other Income Expense Net | -14 M | -13.3 M | |
| Net Income | 984.8 M | 1 B | |
| Income Tax Expense | 289.5 M | 304 M | |
| Net Income Applicable To Common Shares | 836.4 M | 878.2 M | |
| Net Income From Continuing Ops | 984.8 M | 1 B | |
| Non Operating Income Net Other | 3.8 M | 3.6 M | |
| Interest Income | 162.7 M | 170.8 M | |
| Net Interest Income | 103.4 M | 108.6 M | |
| Change To Netincome | 195 M | 100.5 M | |
| Net Income Per Share | 21.04 | 22.09 | |
| Income Quality | 0.99 | 1.06 | |
| Net Income Per E B T | 0.77 | 0.92 |
United Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on United Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of United Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the United Therapeutics' important profitability drivers and their relationship over time.
Use United Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.United Therapeutics Pair Trading
United Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your United Therapeutics position
In addition to having United Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Goods Thematic Idea Now
Consumer Goods
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Consumer Goods theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Goods Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.